Yao‐ming Huang

Biogen (United States)

Papers

1

Total Citations

5

H-Index

1

About

Yao‐ming Huang is a leading figure in bioprocess development, with a primary focus on accelerating the clinical translation of novel therapeutics through high‐throughput cell culture technologies. His most cited work, a 2015 case study on a monoclonal antibody (mAb), demonstrates how leveraging high‐throughput systems can dramatically compress development timelines for early‐phase clinical material production. This contribution addresses a critical industry bottleneck: the need to advance an increasing number of complex biologics into the clinic without sacrificing quality or yield. By systematically optimizing cell culture parameters, Huang’s research provides a robust framework for streamlining the path from discovery to first-in-human trials. His work has garnered over 5 citations, reflecting its practical value for biopharmaceutical engineers and process scientists. Huang’s achievements underscore a commitment to bridging the gap between laboratory innovation and clinical application, making him a key resource for students and researchers seeking to understand how high‐throughput methodologies can transform the efficiency of biologic drug development.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Leveraging high‐throughput technology to accelerate the time to clinic: A case study of a mAb
5 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Biogen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago